Overview
The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study (STML-401-0521).
Eligibility
Inclusion Criteria:
- Alive, deceased, or unreachable participants (as permitted by local regulation), aged ≥18 years at the start of first-line treatment for BPDCN, and treated with chemotherapy regimens (at a minimum) as first-line treatment for BPDCN from May 2016
- Diagnosed with BPDCN, based on clinical, laboratory, and imaging (where performed per institutional practice) assessments, with a demonstration of a specific immunophenotype (either by immunohistochemistry or flow cytometry), particularly CD4, CD56, and CD123
- Participants (or their legally authorized representatives) who have signed the informed consent and privacy form, where required as per local regulation
Exclusion Criteria:
- Participant has received an investigational agent as first-line therapy for BPDCN
- Participant has received first-line therapy for BPDCN in an interventional clinical trial
